Haplotype analysis of these two SNPs showed that carriers of the GA haplotype were shorter than carriers of each of the other three haplotypes (p<0.001 for all comparisons). Conclusion: We did not confirm the previously reported associations between IGF2 polymorphisms and BMI. However our results suggest that common variation in the IGF2 gene may be associated with adult height. IGF2 could be considered as a candidate gene for future research on mechanisms for the association between height and chronic diseases such as cancer, diabetes and coronary heart disease. Common allelic variants in IGF2 have been associated with body weight and BMI in large population-based studies. In a study of 2,500 UK middle-aged men, the IGF2 ApaI (820 G/A) minor allele homozygotes had higher serum IGF-II concentrations and lower BMI and body weight than wild-type homozygotes (8). A subsequent study in the same population investigated 11 other polymorphic markers in IGF2, and found that two further IGF2 SNPs were independently associated with BMI (9): minor allele homozygotes at 6815 A/T also had lower BMI, while minor allele homozygotes at 1156 T/C had higher BMI than wild-type homozygotes (9). By contrast, a separate study of 500 healthy men and women found that ApaI 820 G/A minor allele homozygotes had higher fat mass than wild-type homozygotes (10).
The Insulin-like growth factor 2 gene (IGF2) is exclusively paternally expressed, and maternally imprinted, and plays a key role in fetal growth and development (1, 2) .
Mice with null mutations in the Igf2 gene exhibit decreased fetal growth (3) . In humans IGF2 under-expression caused by methylation defects results in the low birth weight Silver-Russell syndrome (4) , and conversely, loss-of-imprinting leading to IGF2 over-expression results in the Beckwith-Wiedemann somatic overgrowth syndrome (5) .
In postnatal life, Igf2 expression in mice is repressed in all tissues except the brain, and deregulation of Igf2 expression results in postnatal overgrowth (6) . In pigs a quantitative trait locus for muscle growth and leanness has been identified in the IGF2 region (7) . In humans, IGF2 is biallelically expressed in the liver in postnatal life, and the syndromes of IGF2 under-and over-expression exhibit postnatal growth failure and growth acceleration respectively (4, 5) .
Common allelic variants in IGF2 have been associated with body weight and BMI in large population-based studies. In a study of 2,500 UK middle-aged men, the IGF2 ApaI (820 G/A) minor allele homozygotes had higher serum IGF-II concentrations and lower BMI and body weight than wild-type homozygotes (8) . A subsequent study in the same population investigated 11 other polymorphic markers in IGF2, and found that two further IGF2 SNPs were independently associated with BMI (9): minor allele homozygotes at 6815 A/T also had lower BMI, while minor allele homozygotes at 1156 T/C had higher BMI than wild-type homozygotes (9) . By contrast, a separate study of 500 healthy men and women found that ApaI 820 G/A minor allele homozygotes had higher fat mass than wild-type homozygotes (10) .
Given these inconsistent results, we selected the three IGF2 SNPs previously reported to be independently associated with BMI (9) and aimed to confirm this HAL author manuscript inserm-00175886, version 1 association in a UK population of 5000 middle-age men and women. Our secondary aim was to investigate the associations with body fat and also height, as some studies had identified associations with height but these were not highlighted in those reports (8, 10, (18) (19) (20) .
Research design and methods

Population
We analysed data from the Norfolk arm of the European Prospective Investigation of Cancer (EPIC) prospective cohort study. This study has been described elsewhere (11, 12) , but, in brief, is a prospective population study of 25,639 men and women aged between 39 and 79 years, resident in Norfolk, UK. Participants were recruited from age-sex registers of general practices in Norfolk as part of the 10-country collaborative EPIC study designed to investigate dietary and other determinants of cancer. Additional data were obtained in EPIC-Norfolk to enable the assessment of determinants of other diseases. The sub-cohort used for this study is a random sample of 5000 of the participants who were free of disease at baseline (cancer, coronary heart disease and diabetes), who had completed arrayed DNA samples, complete food frequency questionnaires, and HbA1C and BMI measured at two clinical assessments separated by an average of 3 years (13) (see Table 1 for clinical characteristics). All participants gave informed consent.
Measurements
All participants completed a detailed health and lifestyle questionnaire, which included a question on birth weight. Anthropometric measurements were taken with participants dressed in light clothing and no shoes. Standing height was measured to the nearest 0.1 cm using a stadiometer, and weight was measured to the nearest 100 g using Salter scales (Salter Brecknell Weighing Products, Fairmont, Minnesota). BMI was calculated as weight (kg)/height (m) 2 . At follow-up only, sitting height was additionally measured, and leg length was calculated as the difference between overall height and sitting height, plus the height of the measuring stool used for the sitting HAL author manuscript inserm-00175886, version 1 height measurements. Trunk length was calculated as the difference between leg length and total height. Also at follow-up, a Tanita TBF-531 bioimpedance analyzer was used to determine percent body fat, to the nearest 0.5%.
SNPs choice
In the Northwick Park Heart Study II (NPHSII), the authors conducted a systematic search for variants across the exons, the intron/exon boundaries and intron three of the IGF2 gene, and identified 12 different markers (9) . Four SNPs were associated with BMI, of which two were in strong linkage disequilibrium (LD) (pairwise coefficient = 0.87). We therefore selected three SNPs which were not in LD 
Genotyping
All SNPs were genotyped using Custom TaqMan® assays (Applied Biosystems, Warrington, UK) on an ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems, Warrington, UK). Details for all genotyping primers, probes and PCR conditions are available upon request from the corresponding author. The three SNPs had a genotyping call rate above 93% and all of the duplicate controls used in the study set were fully concordant.
Statistical analysis
Each SNP was tested for Hardy-Weinberg equilibrium using the appropriate χ Haplotype analysis was undertaken using the SNPs which remained independently associated with height after a backwards elimination regression analysis. Because phase was unknown, assignment of haplotype probabilities was performed using the SNPHAP program (14, 15). We then used the qhapipf program in STATA to test whether the haplotypes explained more of the variance in height than the genotypes considered independently (16) . Finally, tests for main haplotype effects were performed using a linear model, adjusted for age and gender, weighted by haplotype probability, and clustered by the individual identification to obtain robust standard errors (STATA regression command xi:regres).
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Results
Genotype frequencies for the three SNPs are provided in Table 2 genotypes were confirmed on re-genotyping of the whole cohort. The genotype frequencies were similar in women (40%, 45% and 15% for the GG, GA and AA respectively) and in men (38%, 46% and 15%); however, the deviation was significant only in women (p=0.017 vs p=0.32 in men) and is likely explained by random sampling. were very similar with trunk length and leg length for all SNPs. Birth weight and body fat percent were only available for 2235 and 3750 individuals respectively and no significant association was observed with genotype for either of these outcomes.
Adjusted means for BMI and height by genotype are displayed separately in men and women in Table 4 and Table 5 respectively. No association with BMI was disclosed. The pattern of association with height was similar in men and women for the 1156 T/C (G/A) and the 820 G/A SNPs, but was stronger in women than in men for 1156 T/C (G/A) (p=0.002 vs p=0.37 under the co-dominant model).
In a backwards elimination multiple regression analysis, 1156 T/C (G/A) and 820
G/A (ApaI) remained independently and significantly associated with height (p=0.003 and p=0.037 respectively).
The frequencies for the haplotypes corresponding to those two SNPs, and the age and sex adjusted mean height according to the haplotypes are presented in Figure 1 .
The overall association between haplotypes and height was highly significant (p=0.0002). The haplotypes explained more of the variability in height than when the SNPs were considered independently (p=0.0391). Mean height of individuals with the haplotype GA (frequency of 18.6%) was significantly lower than that of any other haplotype (p<0.001 with AG, AA and GG). Among the remaining haplotypes, only a weak difference was observed between AG and GG (p=0.075).
Discussion
This study of around 5,000 middle age women and men from a population-based cohort provides no evidence for an association between IGF2 common polymorphisms and indices of obesity. However, all three SNPs were associated with height, and similar trends were seen in men and women separately. Our results suggest a role of the IGF2 gene in adult height, which may be consistent with the action of IGF-II protein as a growth factor.
It was previously reported in the NPHSII Study of men only, that the three IGF2 polymorphisms we selected were independently associated with BMI (8, 9, 17).
However, our study in a larger number of individuals including both men and women, did not support that observation. Another study in a Caucasian population showed that the IGF2 ApaI polymorphism was related to fat mass, but the association was in the opposite direction to that in the NPHSII (10). Furthermore O'Dell et al. did not find an association between the ApaI polymorphism and body weight in their sample of young adults from NPHSII (8) , in contrast to their older population. They concluded that the effect on BMI might occur only later in life, possibly as a consequence of interaction with environmental factors related to age (8) . Since these factors are likely to vary between populations, gene-environmental interactions could explain the discrepancies observed between the studies. However, in our population with a wide age range of men and women (39 to 79 years), we did not observe any significant interaction between the effects of age and genotypes. Therefore, the associations identified in the original study between the 3 SNPs and BMI could be false-positives; however, discrepant findings between studies could also arise from differences in subject ascertainment or population structure.
However, consistent with our current findings those previous studies also found associations between IGF2 polymorphisms and adult height, although these findings were not highlighted in those reports. First, in the NPHSII population a trend for an association between the 820 G/A (ApaI) and height was found. Consistent with our findings GG homozygotes tended to be taller than AA (8): the size of the effect (0.7 cm difference; p=0.10) was comparable to our study but the sample size of that study was smaller (8) . The absence of this association could be explained by a lack of power in our study, as the information on birth weight was missing for more than half of the population. 
